London, United Kingdom
Neobe Therapeutics, founded in 2021 and headquartered in the United Kingdom, is at the forefront of biotechnological innovation in the Health Care and Health and Wellness industries. The company's mission, encapsulated in its slogan, is to "Engineer live biotherapeutics to disrupt the tumour microenvironment and enable immunotherapies for non-responders."
Currently, only about 20% of patients with solid tumors benefit from immunotherapies due to an immunosuppressive microenvironment. Neobe Therapeutics addresses this critical challenge by engineering tumour-colonizing bacteria. These innovations target immune-excluded tumors locally, minimizing systemic toxicities and enhancing drug efficacy, potentially transforming non-responders into responders by increasing immune cell infiltration.
In its latest funding milestone, Neobe Therapeutics raised $2.34M in a Seed Round on February 29, 2024, with backing from notable investors such as 2048 Ventures, Pioneer Group, Discovery Park Ventures, Deep Science Ventures, and Cancer Research Horizons. This financial boost underscores strong investor confidence in the company's pioneering approach.
